home / stock / artl / artl news

ARTL News and Press, Artelo Biosciences Inc. From 05/11/23

Stock Information
Company Name: Artelo Biosciences Inc.
Stock Symbol: ARTL
Market: OTC
Website: artelobio.com
Menu
ARTL ARTL Quote ARTL Short ARTL News ARTL Articles ARTL Message Board
Get ARTL Alerts

News, Short Squeeze, Breakout and More Instantly...
ARTL - Artelo Biosciences Reports First Quarter 2023 Financial Results and Provides Business Update

SOLANA BEACH, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. ( Nasdaq: ARTL ) , a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today r...
ARTL - ARTL, HUDI and CXAI are among the mid-day movers

2023-04-28 12:33:58 ET Gainers: AGBA Group Holding  ( AGBA ) +134% . Huadi International Group  ( HUDI ) +55% . Top KingWin ( TCJH ) +50% . MultiMetaVerse Holdings  ( MMV ) +44% . U Power Limited Ordinary ( UCAR ) +4...

ARTL - Baudax, Petros top healthcare gainers; Tracon, Maia among losers

2023-04-25 10:06:07 ET Gainers: Baudax Bio ( BXRX ) +48% . Petros Pharmaceuticals ( PTPI ) +48% . Morphic Holding ( MORF ) +22% . Arrowhead Pharmaceuticals ( ARWR ) +17% . Medpace Holdings ( MEDP ) +17% . Losers: Trac...

ARTL - Artelo Biosciences Initiates the Phase 2a Portion of its CAReS Trial EvaluatingART27.13 for the Treatment of Cancer-Related Anorexia and Weight Loss

SOLANA BEACH, Calif., April 25, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today annou...
ARTL - Artelo Biosciences GAAP EPS of -$3.56

2023-03-31 08:49:48 ET Artelo Biosciences press release ( NASDAQ: ARTL ): FY GAAP EPS of -$3.56. As of December 31, 2022, the Company had approximately $17.5 million in cash and marketable securities, compared to $25.6 million as of December 31, 2021 For further deta...

ARTL - Artelo Biosciences Reports Fiscal 2022 Year-End Financial Results and Provides Business Update

SOLANA BEACH, Calif., March 31, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. ( Nasdaq:ARTL ), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today repor...

ARTL - Artelo Biosciences to Present at MicroCap Rodeo's Annual Winter Wonderland - Best Ideas Virtual Investor Conference on February 22, 2023

SOLANA BEACH, CA / ACCESSWIRE / February 15, 2023 / Artelo Biosciences, Inc. (NASDAQ:ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced that it...
ARTL - Artelo Biosciences Completes Enrollment of the Phase 1b Stage of its CAReS Clinical Trial Evaluating ART27.13 for the Treatment of Cancer-Related Anorexia and Weight Loss

SOLANA BEACH, Calif., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announ...

ARTL - Artelo Biosciences to Present at Sequire Biotechnology Conference on February 2nd

CEO Gregory Gorgas to discuss developments related to the Company’s Cancer Appetite Recovery Study (CAReS) Presentation on Thursday, February 2, 2023 at 1:00 PM ET SOLANA BEACH, Calif., Jan. 26, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a ...

ARTL - Artelo Biosciences GAAP EPS of -$0.82 beats by $0.09

Artelo Biosciences press release ( NASDAQ: ARTL ): Q3 GAAP EPS of -$0.82 beats by $0.09 . As of September 30, 2022, the Company had approximately $19.5 million in cash and investments, compared to $25.6 million as of December 31, 2021. Operating expenses for ...
Previous 10 Next 10